< Back to previous page
Researcher
Ignace Vergote
- Disciplines:Gynaecology and obstetrics, Nursing, Endocrinology and metabolic diseases
Affiliations
- Gynaecological Oncology (Division)
Member
From1 Jan 2012 → Today
Projects
1 - 10 of 12
- Exploring the heterogeneity of rare ovarian cancerDefining (epi)genomic transition from precursor lesion to invasive rare ovarian cancerFrom1 Apr 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Predictive genetic markers for targeted therapy in gynaecological malignancies: bridging the gap between “one-size-fits-all” and more personalised treatment approach.From1 Aug 2019 → 11 Oct 2023Funding: FWO Strategic Basic Research Grant
- Comprehensive genomic and transcriptomic analysis of high grade serous ovarian cancer using single-cell RNA-sequencing.From1 Jan 2019 → 31 Dec 2021Funding: Foundations, funds and other with scientific goal
- Searching for new leads in the diagnosis of ovarian cancerFrom1 Oct 2017 → 30 Sep 2021Funding: Foundations, funds and other with scientific goal
- Comprehensive transcriptomic analysis of high-grade serous tubo-ovarian carcinoma using single-cell RNA-sequencing.From1 Mar 2017 → 5 Jul 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
- From Never to Always Events: in search for mango-momentsFrom1 Nov 2016 → 31 Oct 2018Funding: Nonprofit institution or equivalents
- FIRST PET-MR: Flmeish interuniversity research simultaneous time-of-flight PET-MR scanner.From14 Aug 2014 → 13 Feb 2019Funding: Own budget, for example: patrimony, inscription fees, gifts
- Flemish interuniversity simultaneous time-of-flight PET-MR scanner for research.From14 Aug 2014 → 13 Feb 2019Funding: Hercules - Large scale research infrastructure
- A drug strategy targeting stabilised mutant p53 to fight metastatic plantinum-resistant ovarian cancer.From1 Oct 2013 → 31 Mar 2019Funding: General Activities (Annex IV)
- Dendritic cell immunotherapy in serous ovarian cancer.From1 Oct 2013 → 30 Sep 2016Funding: FWO fellowships
Publications
41 - 50 of 765
- ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium(2023)
Authors: Ignace Vergote
Pages: 46 - 47 - Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines(2022)
Authors: An Coosemans, Ignace Vergote, Abhishek Garg
- A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer(2022)
Authors: Ignace Vergote
Pages: 213 - 225 - Updated Interim Results of the Clinical Performance Evaluation of a Novel Deep Learning Solution for Homologous Recombination Deficiency Detection(2022)
Authors: Ignace Vergote
Pages: S93 - S93 - Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial(2022)
Authors: Ignace Vergote
Pages: 221 - 231 - Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe(2022)
Authors: Ignace Vergote
Pages: 3 - 10 - EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer(2022)
Authors: Ignace Vergote
Pages: 299 - 309 - Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)(2022)
Authors: Ignace Vergote
Pages: S790 - S791 - Role of CA125 in patients included in the DESKTOP III/ENGOT-ov20 trial(2022)
Authors: Ignace Vergote
Pages: S809 - S809 - A multicenter evaluation of a low pass whole genome sequencing-based solution for homologous recombination deficiency detection(2022)
Authors: Ignace Vergote
Pages: S811 - S812
Patents
1 - 1 of 1
- Methods for diagnosing ovarian cancer (Inventor)